Guaifenesin
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Guaifenesin: From Unspecified Indication to Nasal Cavity Disease
One-Sentence Summary
Guaifenesin (DrugBank DB00874) is a widely used mucolytic/expectorant; no original indication license data is present in this Evidence Pack. The TxGNN model predicts it may be effective for Nasal Cavity Disease, with 1 clinical trial and 2 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No license/indication data available (drug not on file with US market approval) |
| Predicted New Indication | Nasal Cavity Disease |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L2 |
| US Market Status | 未上市 (Not marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action (MOA) data is not available in this Evidence Pack. Based on known information, guaifenesin is a mucolytic/expectorant that reduces the viscosity of respiratory and nasal secretions and promotes ciliary clearance. While this pack does not record an original approved indication, this drug class is broadly used clinically for conditions involving thick mucus/nasal secretions.
The pathophysiology of nasal cavity disease (e.g., chronic rhinitis, sinusitis) centers on mucus retention and impaired ciliary clearance. Guaifenesin’s pharmacological effect of thinning secretions and promoting ciliary clearance has a direct physiological link to this mechanism, giving the TxGNN prediction reasonable mechanistic plausibility.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01364467 | Phase 2 | Completed | 30 | 14-day randomized, placebo-controlled, masked pilot trial of oral guaifenesin for pediatric chronic rhinitis (ages 7-18), assessing nasal symptoms via the SN-5 survey, nasal airway volume, and secretion biophysical properties. Relevance grade A, but small pilot sample limits statistical power for confirmatory conclusions. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9065342 | 1997 | Review/Cohort | American Journal of Rhinology | Management experience with 22 adult cystic fibrosis patients with chronic sinusitis, discussing treatment approaches including mucolytics. |
| 12487405 | 2002 | Review | Logopedics, Phoniatrics, Vocology | Discusses guaifenesin-containing decongestants as a treatment strategy for hidden respiratory allergies affecting voice users. |
US Market Information
Currently no US market authorization (NDA) records are available in this Evidence Pack (total licenses: 0).
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA label warnings/contraindications are marked as a Blocking data gap (DG001) and could not be retrieved — this must be resolved before any S1 safety pre-assessment.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence currently rests on a single small (N=30) Phase 2 pilot trial and two loosely related literature reports; safety label data (warnings/contraindications) is a Blocking-severity gap, so the candidate cannot proceed to S1 safety pre-assessment, and no US market/license history is on file to support risk context.
To proceed, the following is needed:
- TFDA/FDA package insert warnings and contraindications (DG001, Blocking)
- Detailed mechanism of action (MOA) data (DG002, High)
- A larger, adequately powered confirmatory trial for chronic rhinitis / nasal cavity disease
- Drug-drug interaction (DDI) data (currently not found)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.